Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11539989 | 0.86 | ALDH1A1 (0.43) | CYP3A4TSHRGAAALDH1A1MAPT | |
| SCHEMBL2588967 | 0.82 | ALDH1A1 (0.41) | CYP3A4TSHRALDH1A1MAPTMEN1 | |
| SCHEMBL4923833 | 0.79 | HTT (0.49) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL653173 | 0.79 | FSCN1 (0.51) | CYP3A4TSHRGAAALDH1A1MAPT | |
| SCHEMBL6224663 | 0.78 | TSHR (0.42) | TSHRGAAALDH1A1MAPTMEN1 | |
| SCHEMBL14662766 | 0.77 | POLB (0.42) | CYP3A4GAAALDH1A1MAPTKDM4E | |
| SCHEMBL6098009 | 0.74 | GAA (0.42) | CYP3A4TSHRGAAALDH1A1MAPT | |
| SCHEMBL4919799 | 0.74 | SIGMAR1 (0.42) | CYP3A4TSHRGAAALDH1A1MAPT | |
| SCHEMBL3429510 | 0.73 | POLB (0.39) | TSHRGAAALDH1A1MAPTMEN1 | |
| SCHEMBL3426424 | 0.71 | KDM4E (0.39) | CYP3A4TSHRALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2007-11-08 | — | — | US | disclosed |
| EP-1416931-B1 | INHIBITORS OF POLYQ-AGGREGATION | MAX PLANCK GESELLSCHAFT (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-06-09 | — | — | US | disclosed |
| EP-1416931-A1 | INHIBITORS OF POLYQ-AGGREGATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003015772-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | HTT, ATXN2, ATXN2L | CYP3A4 4340/4885TSHR 2566/4885GAA 243/4885 |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | HTT, ATXN2, ATXN2L | CYP3A4 4340/4885TSHR 2566/4885GAA 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.